This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal …

Geographic AtrophyStargardt DiseaseRPE-mediated Maculopathy+1 more

~Estimated

~$10 – $8,750

Cellio Therapeutics IncNCT07594236

Observational

Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Retinal DiseaseAge-Related Macular DegenerationRetinitis Pigmentosa+15 more

~Estimated

~$10 – $7,500

MD Stem CellsNCT03011541